Exacerbation of disease symptoms was more frequently observed in patients whose cancer treatment was initiated in the active phase of the autoimmune disease, while the use or absence of immunosuppressive therapy did not significantly affect the severity of autoimmune symptoms after starting anti–PD-1 or anti–PD-L1 therapy (36 % vs. 20%, p = 0.43). The gene discussed is CD274; the disease is autoimmune disease.